VBI Vaccines Q3 EPS $(0.38) Misses $(0.14) Estimate, Sales $6.62M Miss $13.25M Estimate
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines (NASDAQ:VBIV) reported a Q3 EPS loss of $(0.38), significantly missing the $(0.14) estimate, and sales of $6.62M, which also fell short of the $13.25M estimate. Despite these misses, the reported loss and sales figures represent an 87.33% decrease in losses and a 1.99K% increase in sales compared to the same period last year.
November 14, 2023 | 9:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
VBI Vaccines missed Q3 EPS and sales estimates by a wide margin, reporting an EPS loss of $(0.38) and sales of $6.62M against expectations of $(0.14) and $13.25M, respectively.
The significant miss in both EPS and sales estimates is likely to negatively impact investor confidence and could lead to a short-term decline in VBIV's stock price. The magnitude of the miss suggests underlying issues that may concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100